Completed PHASE2 INTERVENTIONAL 2-arm NCT00819650

A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection

Eastern Hepatobiliary Surgical Hospital

Sponsor: Eastern Hepatobiliary Surgery Hospital

Interventions Licartin (generic name,[131I]metuximab injection)

Updated 5 times since 2017 Last updated: Mar 30, 2016 Started: Dec 31, 2008 Primary completion: Dec 31, 2009 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00819650, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains completed. Sponsored by Eastern Hepatobiliary Surgery Hospital, it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Hepatobiliary Surgery Hospital

Data source: Eastern Hepatobiliary Surgery Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China